MovDisordV3, PascalFrancis, Corpus, bibRecord, 001064

Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations

Identifieur interne : 001064 ( PascalFrancis/Corpus ); précédent : 001063; suivant : 001065

Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations

Auteurs : Albert F. G. Leentjens ; Kathy Dujardin ; Laura Marsh ; Pablo Martinez-Martin ; Irene H. Richard ; Sergio E. Starkstein ; Daniel Weintraub ; Cristina Sampaio ; Wemer Poewe ; Oliver Rascol ; Glenn T. Stebbins ; Christopher G. Goetz

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0536677

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Etat dépressif, Pathologie du système nerveux, Anhédonie, Recommandation, Psychométrie, Validité, Fiabilité, Apathie.

English descriptors

KwdEn :
- Anhedonia, Apathy, Depression, Nervous system diseases, Parkinson disease, Psychometrics, Recommendation, Reliability, Validity.

Abstract

Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 14`
A08	`01`	`1`	`ENG`	`@1 Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations`
A11	`01`	`1`		`@1 LEENTJENS (Albert F. G.)`
A11	`02`	`1`		`@1 DUJARDIN (Kathy)`
A11	`03`	`1`		`@1 MARSH (Laura)`
A11	`04`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`05`	`1`		`@1 RICHARD (Irene H.)`
A11	`06`	`1`		`@1 STARKSTEIN (Sergio E.)`
A11	`07`	`1`		`@1 WEINTRAUB (Daniel)`
A11	`08`	`1`		`@1 SAMPAIO (Cristina)`
A11	`09`	`1`		`@1 POEWE (Wemer)`
A11	`10`	`1`		`@1 RASCOL (Oliver)`
A11	`11`	`1`		`@1 STEBBINS (Glenn T.)`
A11	`12`	`1`		`@1 GOETZ (Christopher G.)`
A14	`01`			`@1 Department of Psychiatry, Maastricht University Hospital @2 Maastricht @3 NLD @Z 1 aut.`
A14	`02`			`@1 Neurology and Movement Disorders Unit, Lille University Hospital @2 Lille @3 FRA @Z 2 aut.`
A14	`03`			`@1 Department of Psychiatry, Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 3 aut.`
A14	`05`			`@1 Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health @2 Madrid @3 ESP @Z 4 aut.`
A14	`06`			`@1 Department of Neurology, University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 5 aut.`
A14	`07`			`@1 Department of Psychiatry, University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 5 aut.`
A14	`08`			`@1 school of Psychiatry, University of Western Australia and Fremantle Hospital @2 Fremantle, Western Australia @3 AUS @Z 6 aut.`
A14	`09`			`@1 Department of Psychiatry, University of Pennsylvania School of Medicine @2 Philadelphia, Pennsylvania @3 USA @Z 7 aut.`
A14	`10`			`@1 Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine @3 PRT @Z 8 aut.`
A14	`11`			`@1 Department of Neurology. University Hospital @2 Innsbruck @3 AUT @Z 9 aut.`
A14	`12`			`@1 Laboratoire de Pharmacologie Medicate et Clinique @2 Toulouse @3 FRA @Z 10 aut.`
A14	`13`			`@1 Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine @2 Atlanta, Georgia @3 USA @Z 11 aut.`
A14	`14`			`@1 Department of Neurological Services, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 12 aut.`
A20				`@1 2004-2014`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000184512460080`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 40 ref.`
A47	`01`	`1`		`@0 08-0536677`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Etat dépressif @5 02`
C03	`02`	`X`	`ENG`	`@0 Depression @5 02`
C03	`02`	`X`	`SPA`	`@0 Estado depresivo @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Anhédonie @5 09`
C03	`04`	`X`	`ENG`	`@0 Anhedonia @5 09`
C03	`04`	`X`	`SPA`	`@0 Anhedonia @5 09`
C03	`05`	`X`	`FRE`	`@0 Recommandation @5 10`
C03	`05`	`X`	`ENG`	`@0 Recommendation @5 10`
C03	`05`	`X`	`SPA`	`@0 Recomendación @5 10`
C03	`06`	`X`	`FRE`	`@0 Psychométrie @5 11`
C03	`06`	`X`	`ENG`	`@0 Psychometrics @5 11`
C03	`06`	`X`	`SPA`	`@0 Psicometría @5 11`
C03	`07`	`X`	`FRE`	`@0 Validité @5 12`
C03	`07`	`X`	`ENG`	`@0 Validity @5 12`
C03	`07`	`X`	`SPA`	`@0 Validez @5 12`
C03	`08`	`X`	`FRE`	`@0 Fiabilité @5 13`
C03	`08`	`X`	`ENG`	`@0 Reliability @5 13`
C03	`08`	`X`	`SPA`	`@0 Fiabilidad @5 13`
C03	`09`	`X`	`FRE`	`@0 Apathie @4 CD @5 96`
C03	`09`	`X`	`ENG`	`@0 Apathy @4 CD @5 96`
C03	`09`	`X`	`SPA`	`@0 Apatía @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Trouble de l'humeur @5 42`
C07	`05`	`X`	`ENG`	`@0 Mood disorder @5 42`
C07	`05`	`X`	`SPA`	`@0 Trastorno humor @5 42`
N21				`@1 350`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0536677 INIST
ET :	Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations
AU :	LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.); WEINTRAUB (Daniel); SAMPAIO (Cristina); POEWE (Wemer); RASCOL (Oliver); STEBBINS (Glenn T.); GOETZ (Christopher G.)
AF :	Department of Psychiatry, Maastricht University Hospital/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Department of Psychiatry, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Department of Neurology, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health/Madrid/Espagne (4 aut.); Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); Department of Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); school of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle, Western Australia/Australie (6 aut.); Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, Pennsylvania/Etats-Unis (7 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine/Portugal (8 aut.); Department of Neurology. University Hospital/Innsbruck/Autriche (9 aut.); Laboratoire de Pharmacologie Medicate et Clinique/Toulouse/France (10 aut.); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine/Atlanta, Georgia/Etats-Unis (11 aut.); Department of Neurological Services, Rush University Medical Center/Chicago, Illinois/Etats-Unis (12 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 14; Pp. 2004-2014; Bibl. 40 ref.
LA :	Anglais
EA :	Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Etat dépressif; Pathologie du système nerveux; Anhédonie; Recommandation; Psychométrie; Validité; Fiabilité; Apathie
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Trouble de l'humeur
ED :	Parkinson disease; Depression; Nervous system diseases; Anhedonia; Recommendation; Psychometrics; Validity; Reliability; Apathy
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Mood disorder
SD :	Parkinson enfermedad; Estado depresivo; Sistema nervioso patología; Anhedonia; Recomendación; Psicometría; Validez; Fiabilidad; Apatía
LO :	INIST-20953.354000184512460080
ID :	08-0536677

Links to Exploration step

Pascal:08-0536677

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="05"><s1>Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Wemer" sort="Poewe, Wemer" uniqKey="Poewe W" first="Wemer" last="Poewe">Wemer Poewe</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology. University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="12"><s1>Laboratoire de Pharmacologie Medicate et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0536677</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0536677 INIST</idno>
<idno type="RBID">Pascal:08-0536677</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001064</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="05"><s1>Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Wemer" sort="Poewe, Wemer" uniqKey="Poewe W" first="Wemer" last="Poewe">Wemer Poewe</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology. University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="12"><s1>Laboratoire de Pharmacologie Medicate et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anhedonia</term>
<term>Apathy</term>
<term>Depression</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychometrics</term>
<term>Recommendation</term>
<term>Reliability</term>
<term>Validity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Etat dépressif</term>
<term>Pathologie du   système nerveux</term>
<term>Anhédonie</term>
<term>Recommandation</term>
<term>Psychométrie</term>
<term>Validité</term>
<term>Fiabilité</term>
<term>Apathie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>14</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEENTJENS (Albert F. G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RICHARD (Irene H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STARKSTEIN (Sergio E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WEINTRAUB (Daniel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>POEWE (Wemer)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>RASCOL (Oliver)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>STEBBINS (Glenn T.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle, Western Australia</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neurology. University Hospital</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Laboratoire de Pharmacologie Medicate et Clinique</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>2004-2014</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000184512460080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>40 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0536677</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Depression</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Anhédonie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Anhedonia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Anhedonia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Psychométrie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Psychometrics</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Psicometría</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Validité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Validity</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Validez</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Fiabilité</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Reliability</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Fiabilidad</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Apathie</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Apathy</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Apatía</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>42</s5>
</fC07>
<fN21><s1>350</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0536677 INIST</NO>
<ET>Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations</ET>
<AU>LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.); WEINTRAUB (Daniel); SAMPAIO (Cristina); POEWE (Wemer); RASCOL (Oliver); STEBBINS (Glenn T.); GOETZ (Christopher G.)</AU>
<AF>Department of Psychiatry, Maastricht University Hospital/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Department of Psychiatry, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Department of Neurology, Johns Hopkins University School of Medicine/Baltimore, Maryland/Etats-Unis (3 aut.); Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health/Madrid/Espagne (4 aut.); Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); Department of Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (5 aut.); school of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle, Western Australia/Australie (6 aut.); Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, Pennsylvania/Etats-Unis (7 aut.); Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine/Portugal (8 aut.); Department of Neurology. University Hospital/Innsbruck/Autriche (9 aut.); Laboratoire de Pharmacologie Medicate et Clinique/Toulouse/France (10 aut.); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine/Atlanta, Georgia/Etats-Unis (11 aut.); Department of Neurological Services, Rush University Medical Center/Chicago, Illinois/Etats-Unis (12 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 14; Pp. 2004-2014; Bibl. 40 ref.</SO>
<LA>Anglais</LA>
<EA>Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Etat dépressif; Pathologie du système nerveux; Anhédonie; Recommandation; Psychométrie; Validité; Fiabilité; Apathie</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Trouble de l'humeur</FG>
<ED>Parkinson disease; Depression; Nervous system diseases; Anhedonia; Recommendation; Psychometrics; Validity; Reliability; Apathy</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Mood disorder</EG>
<SD>Parkinson enfermedad; Estado depresivo; Sistema nervioso patología; Anhedonia; Recomendación; Psicometría; Validez; Fiabilidad; Apatía</SD>
<LO>INIST-20953.354000184512460080</LO>
<ID>08-0536677</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001064 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001064 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0536677
   |texte=   Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations

Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri